Adcomm again votes to pull controversial pre-term birth drug from the market

The FDA’s Obstetrics, Reproductive and Urologic Drugs Advisory Committee of outside experts voted 14-1 to pull Covis Pharma’s controversial preterm birth drug from the market after its confirmatory trial from 2018 failed to confirm the drug’s benefit for babies or mothers.